Milesfarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 2,015 | 8,921 | 26,816 | 9,686 | 14,862 | 14,768 | 30,820 | 26,884 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -473 | -704 | 9,480 | 3,642 | -3,809 | -3,087 | 6,054 | 15,455 |
| Equity | -1,702 | -986 | 8,506 | 12,148 | 8,340 | 5,253 | 11,307 | 26,762 |
| Liabilities | 4,005 | 4,962 | 5,644 | 6,415 | 796 | 5,354 | 1,907 | 1,672 |
| Non-current assets | 0 | 0 | 0 | 726 | 485 | 242 | 1 | 1 |
| Current assets | 2,303 | 3,976 | 14,150 | 17,837 | 8,651 | 10,365 | 13,213 | 28,433 |
| Total assets | 2,303 | 3,976 | 14,150 | 18,563 | 9,136 | 10,607 | 13,214 | 28,434 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 3,683 | 5,776 | 5,160 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +36.8% | +342.7% | +200.6% | -63.9% | +53.4% | -0.6% | +108.7% | -12.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -20.5% | -17.7% | 67.0% | 19.6% | -41.7% | -29.1% | 45.8% | 54.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 111.5% | 30.0% | -45.7% | -58.8% | 53.5% | 57.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -23.5% | -7.9% | 35.4% | 37.6% | -25.6% | -20.9% | 19.6% | 57.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 0.7 | 0.5 | 0.1 | 1.0 | 0.2 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,015 | 8,921 | 26,816 | 9,686 | 14,862 | 14,768 | 30,820 | 26,884 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Milesfarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-26 | 2026-08-02 | 19.88 |
| 2026-07-23 | 2026-07-25 | 19.97 |
| 2026-07-19 | 2026-07-22 | 19.88 |
| 2026-07-16 | 2026-07-17 | 19.88 |
| 2026-06-16 | 2026-06-30 | 19.88 |
| 2026-01-16 | 2026-02-16 | 0.03 |
| 2025-08-28 | 2025-08-29 | 28.29 |
| 2025-08-19 | 2025-08-19 | 28.29 |
| 2024-01-16 | 2024-01-16 | 24.89 |
Milesfarma - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Milesfarma is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-02 | 2026-09-02 | 0.13 |
| 2026-08-31 | 2026-09-01 | 0.01 |
| 2026-08-30 | 2026-08-30 | 0.01 |
| 2026-08-26 | 2026-08-29 | 0.01 |
| 2026-08-25 | 2026-08-25 | 0.0 |
| 2026-08-23 | 2026-08-24 | 0.0 |
| 2026-08-20 | 2026-08-22 | 0.0 |
| 2026-08-19 | 2026-08-19 | 0.0 |
| 2026-08-18 | 2026-08-18 | 0.0 |
| 2026-08-17 | 2026-08-17 | 0.0 |
| 2026-08-13 | 2026-08-16 | 0.0 |
| 2026-08-12 | 2026-08-12 | 0.0 |
| 2026-08-10 | 2026-08-11 | 0.0 |
| 2026-08-09 | 2026-08-09 | 0.0 |
| 2026-08-07 | 2026-08-08 | 0.0 |
| 2026-08-06 | 2026-08-06 | 0.0 |
| 2026-08-05 | 2026-08-05 | 0.0 |
| 2026-08-03 | 2026-08-04 | 0.0 |
| 2026-07-26 | 2026-08-02 | 0.0 |
| 2026-07-07 | 2026-07-25 | 0.0 |
| 2026-07-06 | 2026-07-06 | 0.0 |
| 2026-06-29 | 2026-07-05 | 0.66 |
| 2026-06-01 | 2026-06-04 | 0.09 |
| 2026-04-08 | 2026-04-08 | 26.0 |
| 2026-02-03 | 2026-02-16 | 0.01 |
| 2025-06-24 | 2025-06-25 | 79.19 |
| 2025-04-04 | 2025-04-04 | 26.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Milesfarma, UAB (code 303545350) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €26.9K, down 12.8% year on year from €30.8K in 2024, but still well above the €14.8K reported in 2023, which points to a strong two-year expansion. Profitability improved markedly over the period: net profit rose from a loss of €3.1K in 2023 to a profit of €6.1K in 2024 and €15.5K in 2025. The 2025 profit margin reached 57.5%, supported by a lean cost structure and solid operating efficiency. The balance sheet also strengthened, with total assets increasing to €28.4K in 2025 from €13.2K a year earlier and equity rising to €26.8K. Liabilities remained low at €1.7K, resulting in a debt-to-equity ratio of 0.06 and an equity ratio of 94.1%. Return on equity was 57.8% and return on assets 54.4%, while asset turnover stood at 0.95x. Revenue per employee in 2025 was €26.9K.